{"id":19,"date":"2020-09-07T14:24:10","date_gmt":"2020-09-07T12:24:10","guid":{"rendered":"http:\/\/lekarenkarmel.sk\/?page_id=19"},"modified":"2022-06-13T16:46:57","modified_gmt":"2022-06-13T14:46:57","slug":"sortiment","status":"publish","type":"page","link":"http:\/\/www.lekarenkarmel.sk\/?page_id=19","title":{"rendered":"\u010cl\u00e1nky"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Domov<\/a><\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

\u010cl\u00e1nky<\/a><\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Kontakt<\/a><\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Je \u010das vr\u00e1ti\u0165 sa k lie\u010divej sile pr\u00edrody. SARS-CoV-2 a in\u00e9 nebezpe\u010dn\u00e9 v\u00edrusov\u00e9 ochorenia; mo\u017enosti prevencie, terapie a rekonvalescencie.<\/b><\/h3>

\u00a0<\/p>

Prib\u00fadaj\u00face d\u00f4kazy ukazuj\u00fa, \u017ee vakc\u00edny proti SaRS-CoV-2 neposkytuj\u00fa o\u010dak\u00e1van\u00fa ochranu proti tomuto v\u00edrusu a u pomerne vysok\u00e9ho percenta zao\u010dkovan\u00fdch \u013eud\u00ed doch\u00e1dza k prepuknutiu ochorenia.<\/strong><\/p>

Napr\u00edklad v \u0161t\u00fadii vykonanej v \u0161t\u00e1te Massachusetts, na ktorej participovala aj americk\u00e1 CDC, pribli\u017ene tri \u0161tvrtiny (74 %) pr\u00edpadov SARS-CoV-2 sa vyskytli u plne zao\u010dkovan\u00fdch os\u00f4b (t\u00fdch, ktor\u00ed absolvovali 2 d\u00e1vky mRNA vakc\u00edny Pfizer-BioNTech alebo Moderna).[3] Okrem toho, vakc\u00edny proti SARs-CoV-2 sp\u00f4sobuj\u00fa jednak \u00famrtia,[4] [5] vr\u00e1tane \u00famrt\u00ed dospievaj\u00facich det\u00ed[6] a\u00a0jednak v\u00fdvin viacer\u00fdch v\u00e1\u017enych ochoren\u00ed.[7] [8] [9] [10] Z\u00a0tohto d\u00f4vodu je potrebn\u00e9 poskytn\u00fa\u0165 inform\u00e1cie aj o\u00a0liekoch a\u00a0lie\u010div\u00fdch l\u00e1tkach, ktor\u00e9 s\u00fa na pr\u00edrodnej b\u00e1ze a ktor\u00fdch \u00fa\u010dinky proti SARS-CoV-2 a\u00a0in\u00fdm v\u00edrusov\u00fdm ochoreniam boli preuk\u00e1zan\u00e9 vedeck\u00fdmi \u0161t\u00fadiami.<\/p>

Ivermekt\u00edn<\/b>\u00a0je efekt\u00edvny liek v\u00a0prevencii a\u00a0lie\u010dbe SARS-CoV-2 aj ke\u010f sa tieto jeho \u00fa\u010dinky na t\u00fdch najvy\u0161\u0161\u00edch \u00farovniach (WHO, EMA) neust\u00e1le spochyb\u0148uj\u00fa. Ned\u00e1vna meta-anal\u00fdza (Bryant a\u00a0kol., august 2021) do ktorej bolo zahrnut\u00fdch 15 \u0161t\u00fadi\u00ed a\u00a0ktor\u00e1 bola publikovan\u00e1 v\u00a0\u010dasopise American Journal of Therapeutic v\u0161ak preuk\u00e1zala, \u017ee v\u010dasn\u00e9 u\u017e\u00edvanie ivermekt\u00ednu zn\u00ed\u017eilo \u00famrtnos\u0165 na SARS-CoV-2 a\u017e o\u00a068%.[11]\u00a0 Podobne aj \u010fal\u0161ie meta-anal\u00fdzy a \u0161t\u00fadie preuk\u00e1zali vysok\u00fa \u00fa\u010dinnos\u0165 ivermekt\u00ednu proti SARS-CoV-2,[12] [13] [14] vr\u00e1tane \u0161t\u00fadie, ktorej spoluautorom bol profesor Satoshi \u014cmura,[15] ktor\u00fd spolu s C. Campbellom obdr\u017eali za objav ivermekt\u00ednu Nobelovu cenu. Pod\u013ea vyhl\u00e1senia FLCCC (Frontline Covid-19 Critical Care Alliance) na klinick\u00fdch \u00fa\u010dinkoch ivermekt\u00ednu sa podie\u013ea nielen potla\u010den\u00edm replik\u00e1cie SARS-CoV-2, ale aj blokovania v\u00e4zby v\u00edrusu na hostite\u013esk\u00fa bunku a\u00a0ovplyvnenie z\u00e1palov\u00fdch reakci\u00ed pacienta.[16] Ivermekt\u00edn nie je liek pre zvierat\u00e1, ako sa\u00a0to \u010dasto pods\u00fava. Pou\u017e\u00edva sa v\u00a0hum\u00e1nnej aj veterin\u00e1rnej praxi, \u010do je be\u017en\u00e9 aj u\u00a0mnoh\u00fdch in\u00fdch hum\u00e1nnych liekov. Predsa nikto nezavrhuje antibiotika ako je napr\u00edklad amoxicil\u00edn alebo sulf\u00f3namidy len preto, \u017ee sa pou\u017e\u00edvaj\u00fa vo veterin\u00e1rnej praxi. Na diskredit\u00e1ciu ivermekt\u00ednu sa pou\u017e\u00edvaj\u00fa aj nepravdiv\u00e9 inform\u00e1cie o jeho z\u00e1va\u017en\u00fdch ved\u013eaj\u0161\u00edch \u00fa\u010dinkoch. Ivermekt\u00edn nie je \u017eiadna \u201etvrd\u00e1 ch\u00e9mia,\u201c ale m\u00e1 svoj p\u00f4vod v\u00a0pr\u00edrode, v bakt\u00e9rii Streptomyces avermitilis, ktor\u00e1 bola izolovan\u00e1 z\u00a0p\u00f4dy na pobre\u017e\u00ed ostrova\u00a0Hon\u0161u. Od roku 1987 len spolo\u010dnos\u0165 Merck poskytla viac ako 3,7 miliardy o\u0161etren\u00ed s\u00a0ivermekt\u00ednom[17] a v obvykl\u00fdch d\u00e1vkach (0,2\u20130,4 mg\/kg) sa pova\u017euje u\u00a0\u013eud\u00ed za mimoriadne bezpe\u010dn\u00fd.[18] [19] Ivermekt\u00edn je vo v\u0161eobecnosti dobre tolerovan\u00fd,\u00a0 a to aj pri d\u00e1vke a\u017e 10-n\u00e1sobne vy\u0161\u0161ej (2 mg\/kg) ako je d\u00e1vka odpor\u00fa\u010dan\u00e1 FDA (0,2 mg\/kg).[20] Ivermekt\u00edn je v\u00fdnimo\u010dn\u00e9 antivirotikum inhibuj\u00face nebezpe\u010dn\u00e9 v\u00edrusy, ktor\u00e9 predstavuj\u00fa ve\u013ek\u00fa z\u00e1\u0165a\u017e pre \u013eudsk\u00e9 zdravie.[21] Je \u00fa\u010dinn\u00fd nielen proti SARS-CoV-2, ale aj proti in\u00fdm nebezpe\u010dn\u00fdm v\u00edrusom ako je Zika v\u00edrusu,[22] HIV-1,[23] a\u00a0Dengue v\u00edrus,[24] Chikungunya v\u00edrus,[25] flaviv\u00edrusy (v\u00edrus \u017eltej zimnice, japonskej encefalit\u00eddy a\u00a0pod.).[26] Ivermekt\u00edn je jedine\u010dn\u00fd dar pr\u00edrody, ktor\u00fd m\u00f4\u017ee \u013eudstvu pom\u00f4c\u0165 v\u00a0boji nielen proti SARS-CoV-2, ale aj in\u00fdm v\u00edrusom \u201enezn\u00e1meho\u201d p\u00f4vodu.<\/p>

Okrem ivermekt\u00ednu n\u00e1m pr\u00edroda poskytuje aj \u010fal\u0161ie lie\u010div\u00e9 l\u00e1tky s\u00a0preuk\u00e1zan\u00fdmi \u00fa\u010dinkami proti SARS-CoV-2. Ve\u013ekou n\u00e1dejou s\u00fa\u00a0flavonoidy<\/b>, ktor\u00fdch pou\u017e\u00edvanie m\u00e1 zna\u010dn\u00fd v\u00fdznam pre prevenciu a lie\u010dbu SARS-CoV-2 a\u00a0navy\u0161e s\u00fa bezpe\u010dn\u00e9 pre \u013eudsk\u00fd organizmus. Uk\u00e1zalo sa, \u017ee flavonoidy maj\u00fa siln\u00fa inhibi\u010dn\u00fa aktivitu proti t\u00fdm cie\u013eom SARS-CoV-2, ktor\u00e9 s\u00fa potrebn\u00e9 na u\u013eah\u010denie jeho vstupu do bunky a\u00a0jeho rozmno\u017eovanie ako s\u00fa Mpro (main protease), RBD (Receptor Binding Domain) S prote\u00ednu, RdRp \u00a0(RNA-dependent RNA polymerase), ACE-2 receptor (Angiotensin Converting Enzyme-2) a TMPRSS2 (Human Type 2 Transmembrane Serine). Taktie\u017e bola preuk\u00e1zan\u00e1 imunomodula\u010dn\u00e1 aktivita flavonoidov prostredn\u00edctvom inhib\u00edcie r\u00f4znych proz\u00e1palov\u00fdch cytok\u00ednov a dr\u00e1h zapojen\u00fdch do z\u00e1palov\u00fdch reakci\u00ed. Najzn\u00e1mej\u0161\u00ed z\u00a0flavonoidov je quercetin, ktor\u00fd atakuje SARS-CoV-2 na viacer\u00fdch miestach a\u00a0vykazuje vo\u010di nemu v\u00fdznamn\u00e9 inhibi\u010dn\u00e9 \u00fa\u010dinky, \u010do podporuje jeho pou\u017eitie pri s\u00fa\u010dasn\u00fdch a o\u010dak\u00e1van\u00fdch bud\u00facich prepuknutiach SARS-CoV-2.[27] V\u00fdsledky viacer\u00fdch \u0161t\u00fadi\u00ed uk\u00e1zali, \u017ee\u00a0quercetin<\/b>\u00a0vykazuje dobr\u00fa v\u00e4zbov\u00fa afinitu k Mpro, \u00a0k ACE-2 receptoru a\u00a0k TMPRSS2.[28] [29] [30] Navy\u0161e quercetin blokuje prote\u00e1zu podobn\u00fa 3-chymotryps\u00ednu\u00a0 a prote\u00e1zu podobn\u00fa papa\u00ednu, ktor\u00e9 s\u00fa spolu s RNA-dependentnou RNA polymer\u00e1zou a spike prote\u00ednom hlavn\u00e9 ciele lie\u010denia SARS-CoV-2.[31] V\u00fdsledky ned\u00e1vnej \u0161t\u00fadie (Di Pierro a\u00a0kol., J\u00fan 2021) preuk\u00e1zali, \u017ee quercet\u00edn v\u00fdznamne zni\u017euje potrebu a d\u013a\u017eku hospitaliz\u00e1cie, potrebu neinvaz\u00edvnej oxygenoterapie, presun na jednotku intenz\u00edvnej starostlivosti a\u00a0riziko \u00famrtia.[32]<\/p>

Flavonoidy s\u00fa v pr\u00edrode pomerne hojne zast\u00fapen\u00e9. Najbohat\u0161\u00edm zdrojom napr\u00edklad quercetinu, kaempferolu a myricet\u00ednu s\u00fa \u017elt\u00e1 cibu\u013ea a ku\u010derav\u00fd kel. \u010eal\u0161\u00edmi zdrojmi flavonoidov s\u00fa p\u00f3r, cherry paradajky, brokolica a \u010du\u010doriedky, marhule, jablk\u00e1, \u010dierne hrozno, paradajky, \u010dierny a zelen\u00fd \u010daj. V lek\u00e1r\u0148ach je quercetin dostupn\u00fd od viacer\u00fdch renomovan\u00fdch v\u00fdrobcov. V\u00fdborn\u00e9\u00a0 zlo\u017eenie m\u00e1 slovensk\u00fd produkt\u00a0Covirin<\/b>\u00a0s jedine\u010dnou kombin\u00e1ciou rastlinn\u00fdch lie\u010div\u00fdch l\u00e1tok (quercet\u00edn, kurkum\u00edn, epigallokatechin-3-gal\u00e1t, glycyrrhiz\u00edn, piper\u00edn), miner\u00e1lov (zinok, sel\u00e9n), vitam\u00ednov skupiny B (B3, B9, B12) a vitam\u00ednov C, D a E, ktor\u00e9 sa vz\u00e1jomne dop\u013a\u0148aj\u00fa pri posil\u0148ovan\u00ed imunity proti v\u00edrusom ako je SARS-CoV-2, ale aj rinov\u00edrusom, \u013eudsk\u00fdm papil\u00f3ma v\u00edrusom, herpes simplex a in\u00fdm v\u00edrusom. Covirin obsahuje quercet\u00edn a glycirrhiz\u00edn, lie\u010div\u00e9 l\u00e1tky, ktor\u00e9 maj\u00fa antiv\u00edrusov\u00e9, antitrombotick\u00e9, \u00a0protiz\u00e1palov\u00e9 a imunitu podporuj\u00face \u00fa\u010dinky. Taktie\u017e obsahuje extrakt zo zelen\u00e9ho \u010daju zah\u0155\u0148aj\u00faci katech\u00edny vr\u00e1tene epigallokatechin-3-gal\u00e1tu, ktor\u00fd ma antitrombotick\u00e9 a protiz\u00e1palov\u00e9 \u00fa\u010dinky. Covirin sa odpor\u00fa\u010da nielen ako prevencia proti SARS-CoV-2, ale aj \u013eu\u010fom, ktor\u00ed s\u00fa pozit\u00edvni na SARS-CoV-2,\u00a0 maj\u00fa \u0165a\u017ekosti po prekonan\u00ed Covidu a chc\u00fa posilni\u0165 svoju imunitu, \u010di u\u017e s\u00fa, alebo nie s\u00fa zao\u010dkovan\u00ed. Vzh\u013eadom na jeho antitrombotick\u00e9 \u00fa\u010dinky je potrebn\u00e1 opatrnos\u0165 pri liekoch obsahuj\u00facich warfar\u00edn a in\u00e9 antikoagulanci\u00e1.<\/p>

\u010eal\u0161ou \u00fa\u010dinnou pr\u00edrodnou l\u00e1tkou proti SARS-CoV-2 je\u00a0alic\u00edn<\/b>, ktor\u00e9ho sa nach\u00e1dza v cesnaku. Je u\u017e d\u00e1vnej\u0161ie zn\u00e1me, \u017ee l\u00e1tky obsiahnut\u00e9 v\u00a0cesnaku<\/b>\u00a0maj\u00fa viacer\u00e9 v\u00fdznamn\u00e9 biologick\u00e9 \u00fa\u010dinky vr\u00e1tane antibakteri\u00e1lnych, antiv\u00edrusov\u00fdch, antimykotick\u00fdch, antioxida\u010dn\u00fdch, protiz\u00e1palov\u00fdch a protirakovinov\u00fdch.[33] Yaghoubian\u00a0 a\u00a0kol. (j\u00fan 2021) preuk\u00e1zali, \u017ee alic\u00edn v\u00fdznamne zlep\u0161uje prejavy a sympt\u00f3my SARS-CoV-2 u\u017e po dvoch t\u00fd\u017ed\u0148och lie\u010dby. Alic\u00edn\u00a0 nielen zlep\u0161il klinick\u00e9 pr\u00edznaky, ale zlep\u0161il aj laborat\u00f3rne a r\u00e1diologick\u00e9 \u00fadaje, ktor\u00e9 preuk\u00e1zali jeho terapeutick\u00fd \u00fa\u010dinok pri SARS-CoV-2.[34] V\u00a0\u0161t\u00fadii s\u00a0Calu-3 bunkami p\u013e\u00fac alic\u00edn zru\u0161il odpove\u010f interfer\u00f3nom stimulovan\u00fdch g\u00e9nov hostite\u013ea a vr\u00e1til jeho bunkov\u00e9 dr\u00e1hy na \u00farovne neinfikovan\u00fdch buniek, \u010d\u00edm sa potvrdila antiv\u00edrusov\u00e1 a imunomodula\u010dn\u00e1 aktivita alic\u00ednu.[35] Je zn\u00e1me, \u017ee\u00a0 akt\u00edvne miesto hlavnej prote\u00e1zy SARS-CoV-2, ktor\u00e9 \u0161tiepi jeden\u00e1s\u0165 miest dlh\u00e9ho polyprote\u00ednu, aby sa uvo\u013enili funk\u010dn\u00e9 prote\u00edny potrebn\u00e9 na mno\u017eenie koronav\u00edrusu, obsahuje tiol. A\u00a0pr\u00e1ve alic\u00edn obsahuje reakt\u00edvny tiosulfin\u00e1t, ktor\u00fd m\u00f4\u017ee sp\u00f4sobi\u0165 S-tioalyl\u00e1ciu prote\u00ednu. V\u00a0s\u00fa\u010dasnosti sa alic\u00edn\u00a0pova\u017euje za kovalentn\u00fd inhib\u00edtor SARS-CoV-2 Mpro<\/b>.[36] Cesnak obsahuje vysoko \u00fa\u010dinn\u00e9 zl\u00fa\u010deniny s\u00edry, a\u00a0preto by mal by\u0165 v\u00a0s\u00fa\u010dasnej \u201ecovidovej dobe\u201c ka\u017edodennou s\u00fa\u010das\u0165ou na\u0161ej stravy (tepelne neupraven\u00fd). Aj ke\u010f s\u00fa v\u00a0lek\u00e1r\u0148ach dostupn\u00e9 viacer\u00e9 pr\u00edpravky obsahuj\u00face\u00a0alic\u00edn<\/b>, odporu\u010dil by som \u010derstv\u00fd cesnak, najlep\u0161ie z\u00a0vlastnej produkcie. Kvalita cesnaku je rozhoduj\u00faca. Prchav\u00e9 cesnakov\u00e9 zl\u00fa\u010deniny s\u00edry, ako je tiol-reakt\u00edvny alic\u00edn (diallyltiosulfin\u00e1t) a allylpolysulf\u00e1ny, maj\u00fa najsilnej\u0161ie antiv\u00edrusov\u00e9 \u00fa\u010dinky a je zn\u00e1me, \u017ee stimuluj\u00fa imunitn\u00fd syst\u00e9m ovplyvnen\u00edm produkcie cytok\u00ednov a proz\u00e1palov\u00fdch cytok\u00ednov.<\/p>

Glycirrhiz\u00edn<\/b>, ktor\u00fd sa nach\u00e1dza v\u00a0 rastline Sladk\u00e9 drievko (Glycyrrhiza glabra) je \u010fal\u0161ou \u00fa\u010dinnou pr\u00edrodnou l\u00e1tkou u\u00a0ktorej boli vedeck\u00fdmi \u0161t\u00fadiami preuk\u00e1zan\u00e9 \u00fa\u010dinky proti v\u00edrusom vr\u00e1tane SARS-CoV-2. Hlavn\u00e9 mechanizmy jeho \u00fa\u010dinku zah\u0155\u0148aj\u00fa inhib\u00edciu replik\u00e1cie v\u00edrusov, priamu inaktiv\u00e1ciu v\u00edrusov, inhib\u00edciu z\u00e1palu sprostredkovan\u00e9ho HMGB1\/TLR4, inhib\u00edciu \u03b2-chemok\u00ednov, zn\u00ed\u017eenie v\u00e4zby HMGB1 na DNA s cie\u013eom oslabi\u0165 aktivitu v\u00edrusov a inhib\u00edciu tvorby reakt\u00edvnych foriem kysl\u00edka.[37] [38] [39] [40]<\/p>

Ak sa predsa len podar\u00ed SARS-CoV-2 prelomi\u0165 obrann\u00e9 mechanizmy, ktor\u00e9 poskytuje ivermekt\u00edn, quercetin, alic\u00edn a glycirhizz\u00edn (najlep\u0161ie je u\u017e\u00edva\u0165 ich prevent\u00edvne alebo ich okam\u017eite nasadi\u0165 pri prv\u00fdch pr\u00edznakoch ochorenia), je potrebn\u00e9 \u010d\u00edm najsk\u00f4r vyh\u013eada\u0165 ambulantn\u00fa starostlivos\u0165.<\/p>

Je zn\u00e1me, \u017ee \u013eudia infikovan\u00ed SARS-CoV-2 maj\u00fa zv\u00fd\u0161en\u00e9 riziko\u00a0trombo-embolick\u00fdch pr\u00edhod<\/b>[41] a podobne aj osoby zao\u010dkovan\u00e9 vakc\u00ednami proti SARS-CoV-2.[42] [43] Z tohto d\u00f4vodu je vhodn\u00e9 pou\u017e\u00edva\u0165 pr\u00edrodn\u00e9 lie\u010div\u00e9 l\u00e1tky, ktor\u00e9 m\u00f4\u017eu zn\u00ed\u017ei\u0165 riziko v\u00fdvinu uveden\u00fdch ochoren\u00ed. U\u017e spom\u00ednan\u00fd flavonoid\u00a0quercet\u00edn<\/b>\u00a0zabra\u0148uje zhlukovaniu do\u0161ti\u010diek[44] a jeho v\u00fdznamn\u00fd antitrombotick\u00fd \u00fa\u010dinok bol pozorovan\u00fd aj pri pokro\u010dil\u00fdch \u0161t\u00e1di\u00e1ch rakoviny.[45] Podobne aj u\u00a0glycirrhiz\u00ednu<\/b>\u00a0sa potvrdili v\u00fdznamn\u00e9 antitrombotick\u00e9 \u00fa\u010dinky.[46] [47] \u010eal\u0161ou \u00fa\u010dinnou lie\u010divou l\u00e1tkou, ktor\u00e1 zni\u017euje agreg\u00e1ciu krvn\u00fdch do\u0161ti\u010diek je\u00a0epigallokatechin-3-gal\u00e1t<\/b>, ktor\u00fd sa nach\u00e1dza vo zv\u00fd\u0161enom mno\u017estve najm\u00e4 v\u00a0zelenom \u010daji.[48] V\u0161etky uveden\u00e9 l\u00e1tky s\u00fa obsiahnut\u00e9 napr\u00edklad v\u00a0u\u017e spom\u00ednanom pr\u00edpravku Covirin.<\/p>

Preto\u017ee SARS-CoV-2 sp\u00f4sobuje aj viacer\u00e9 neurologick\u00e9 ochorenia[49] a podobne aj vakc\u00edny proti SARS-CoV-2,[50] bolo by dobr\u00e9 v\u00a0t\u00fdchto pr\u00edpadoch pou\u017e\u00edva\u0165 l\u00e1tky chr\u00e1niace a\u00a0normalizuj\u00face nervov\u00fd syst\u00e9m. Svoj\u00edm v\u00fdborn\u00fdm zlo\u017een\u00ed m\u00f4\u017ee v\u00fdznamne pom\u00f4c\u0165 pr\u00edpravok\u00a0Revitanerv<\/b>, alebo jeho silnej\u0161ia verzia\u00a0Revitanerv strong<\/b>, ktor\u00e9 obsahuj\u00fa skupinu vitam\u00ednov B, kyselinu alfa-lipoov\u00fa a\u00a0Ginko biloba. Z\u00a0lie\u010div\u00fdch rastl\u00edn je to najm\u00e4\u00a0Rozchodnica ru\u017eov\u00e1<\/b>\u00a0(Rhodiola rosea) alebo z\u00a0nej vyroben\u00e9 pr\u00edpravky, ktor\u00e9\u00a0p\u00f4sobia proti autoimunitn\u00fdm po\u0161kodeniam mozgu a\u00a0\u0160i\u0161iak bajkalsk\u00fd<\/b>\u00a0(Scutellaria baicalensis), ktor\u00fd\u00a0je tie\u017e zn\u00e1my svojimi neuroprotektivn\u00fdmi \u00fa\u010dinkami.<\/p>

Vzh\u013eadom na skuto\u010dnos\u0165, \u017ee o\u010dkovanie proti SARS-CoV-2 sa \u010doraz viac jav\u00ed nielen ako nespo\u013eahliv\u00e9 ale aj nebezpe\u010dn\u00e9, je \u010das vr\u00e1ti\u0165 sa k\u00a0lie\u010divej sile pr\u00edrody, ktor\u00e1 sa \u017eia\u013e takmer v\u00f4bec nepropaguje, alebo sa z\u00e1merne zazn\u00e1va. V\u00a0s\u00fa\u010dasnosti v\u0161ak lie\u010div\u00fa silu pr\u00edrody potvrdzuj\u00fa nielen sk\u00fasenosti viacer\u00fdch gener\u00e1ci\u00ed \u013eud\u00ed, ale aj vedeck\u00e9 \u0161t\u00fadie, ktor\u00e9 v\u00a0s\u00favislosti so SARS-CoV-2 preuk\u00e1zali biologick\u00e9 mechanizmy, prostredn\u00edctvom ktor\u00fdch pr\u00edrodn\u00e9 lie\u010div\u00e9 l\u00e1tky efekt\u00edvne \u00fa\u010dinkuj\u00fa proti SARS-CoV-2 a\u00a0in\u00fdm v\u00edrusom.<\/p>

PharmDr. Jozef Laurinec, PhD.<\/p>

\u00a0<\/p>

\u00a0<\/p>

\u00a0<\/p>

\u00a0<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

[1]Acharya CHB,\u00a0\u00a0Schrom J,\u00a0Mitchell AM, et al. No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant. medRxiv. October 2021.\u00a0https:\/\/doi.org\/10.1101\/2021.09.28.21264262<\/a>.<\/p>

[2] Riemersma KK, Grogan BE,\u00a0 Kita-Yarbro A,\u00a0et al. Shedding of Infectious SARS-CoV-2 Despite Vaccination. medRxiv.August 20212.\u00a0https:\/\/doi.org\/10.1101\/2021.07.31.21261387<\/a>.<\/p>

[3] Brown CM, Vostok J, Johnson H, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public \u2212Gatherings Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 1059-1062.<\/p>

[4] Potteg\u00e5rd A, Lund LC, Karlstad \u00d8, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.\u00a0BMJ. May 2021;373:n1114.<\/p>

[5] Cari L, Fiore P, Naghavi Alhosseini M, Sava G, Nocentini G. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data.
Journal of Autoimmunity. August 2021;122:102685.<\/p>

[6] Center for Diseae\u00a0 Control and Prevention. COVID-19 Vaccine Safety in Adolescents Aged 12\u201317 Years \u2014 United States, December 14, 2020\u2013July 16, 2021.\u00a0https:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7031e1.htm<\/a>. Accessed September 22, 2021.<\/p>

[7] Potteg\u00e5rd A, Lund LC, Karlstad \u00d8, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.\u00a0BMJ. May 2021;373:n1114.<\/p>

[8] Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.\u00a0The New England Journal of Medicine. 2021;384(5):403-416.<\/p>

[9] Ozonoff A, Nanishi E, Levy O. Bell\u2019s palsy and SARS-CoV-2 vaccines-an unfolding story \u2013 Authors\u2019 reply [published online ahead of print, 2021 Jun 7].\u00a0The Lancet. Infectious Diseases. July 2021;S1473-3099(21)00323-6.<\/p>

[10] Singh Malhotra H, Gupta P, Prabhu V, et al. COVID-19 vaccination-associated myelitis [published online ahead of print, 2021 Mar 31].\u00a0QJM. 2021;hcab069.<\/p>

[11] Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines.\u00a0American Journal of Therapeutics. Jul-August 2021;28(4):e434-e460.
[12] Kory P, Meduri GU, Varon J, et al. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19.\u00a0American Journal of Therapeutics. 2021;28(3):e299-e318.<\/p>

[13] \u00a0Nardelli P,\u00a0 Zangrillo A, Sanchini G, et al. Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use? May 2021. Signa Vitae; 17(3):3-4.<\/p>

[14] Covid Analysis. Ivermectin is effective for COVID-19: real-time meta analysis of 64 studies. Nov 26, 2020 (Version 138, Oct 26, 2021).\u00a0https:\/\/ivmmeta.com\/<\/a>.<\/p>

[15] Yagisawa M,\u00a0 Foster PJ,\u00a0 Hanaki H,\u00a0 \u014cmura S. Global trends in clinical studies of ivermectin in COVID-19. The Japanese Journal of Antibiotics. March 2021;74(1):44-95.<\/p>

[16] FLCCC Alliance: Ivermectin\u2014A potential global solution to the COVID-19 pandemic. October 31, 2020.\u00a0https:\/\/kitasato-infection-control.info\/swfu\/d\/ivermectin_1.pdf<\/a>.<\/p>

[17] Nicolas P, Maia MF, Bassat Q, Kobylinski KC, Monteiro W, Rabinovich NR, Men\u00e9ndez C, Bardaj\u00ed A, Chaccour C. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. Lancet Glob Health. 2020 Jan;8(1):e92-e100.<\/p>

[18] Banerjee K, Nandy M, Dalai CK, et al.\u00a0 The Battle against COVID 19 Pandemic: What we Need to Know Before we \u201cTest Fire\u201d Ivermectin. Drug Res (Stuttg). 2020 Aug;70(8):337-340. doi: 10.1055\/a-1185-8913.<\/p>

[19] Navarro M, Camprub\u00ed D, Requena-M\u00e9ndez A, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020 Apr 1;75(4):827-834.<\/p>

[20] Guzzo CA, Furtek CI, Porras AG, et al.\u00a0 Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. Journal of Clinical Pharmacology. 2002 Oct;42(10):1122-33.<\/p>

[21] Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer. Antiviral Res. 2020 May;177:104760.<\/p>

[22] Barrows NJ, Campos RK, Powell ST, et al. Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe. 2016 Aug 10;20(2):259-70.<\/p>

[23] Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.\u00a0The Biochemical Journal. 2012;443(3):851-856.<\/p>

[24] Tay MY, Fraser JE, Chan WK, et al. Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin. Antiviral Research. 2013 Sep;99(3):301-6.<\/p>

[25] Varghese FS, Kaukinen P, Gl\u00e4sker S, et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res. 2016 Feb;126:117-24.<\/p>

[26] Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. The Journal of antimicrobial chemotherapy. 2012 Aug;67(8):1884-94.<\/p>

[27] Alzaabi MM, Hamdy R, Ashmawy NS, et al. Flavonoids are promising safe therapy against COVID-19. [published online ahead of print, 2021 May 22].\u00a0Phytochemistry Reviews : Proceedings of the Phytochemical Society of Europe.2021;1-22.<\/p>

[28] Kaul R, Paul P, Kumar S, et al. Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review.\u00a0International Journal of Molecular Sciences. \u00a02021;22(20):11069.<\/p>

[29] Chikhale RV, Gupta VK, Eldesoky GE, et al. Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies. Journal of Biomolecular Structure and Dynamics. 2020 Aug 3:1-16.<\/p>

[30] Alzaabi MM, Hamdy R, Ashmawy NS, et al. Flavonoids are promising safe therapy against COVID-19. [published online ahead of print, 2021 May 22].\u00a0Phytochemistry Reviews : Proceedings of the Phytochemical Society of Europe.2021;1-22.<\/p>

[31] Derosa G, Maffioli P, D\u2019Angelo A\u00a0et al. A role for quercetin in coronavirus disease. 2019 (COVID-19).Phytotherapy Research. 2020 Oct; 35(3):1230-1236,<\/p>

[32] Di Pierro F, Derosa G, Maffioli P, et al.\u00a0 Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. International Journal of General Medicine. 2021 June 8;14:2359-2366.<\/p>

[33] El-Saber Batiha G, Magdy Beshbishy A, G Wasef L, et al. Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum\u00a0L.): A Review.\u00a0Nutrients. 2020;12(3):872.<\/p>

[34] Yaghoubian H, Niktale H, Yazdi AP, et al. Evaluate the Therapeutic Effect of Allicin (L-cysteine) on Clinical Presentation and Prognosis in Patients with COVID-19. European Journal of Translational Myology. 2021 June 18;31(2):9518.<\/p>

[35] M\u00f6sbauer K,\u00a0Fritsch VN,\u00a0\u00a0Adrian L, et al. Allicin inhibits SARS-CoV-2 replication and abrogates the antiviral host response in the Calu-3 proteome. 2021 June. \u00a0bioRxiv. doi:\u00a0https:\/\/doi.org\/10.1101\/2021.05.15.444275<\/a>.<\/p>

[36] Shekh S, Reddy KKA, Gowd KH.\u00a0In silico\u00a0allicin induced\u00a0S-thioallylation of SARS-CoV-2 main protease.\u00a0Journal of sulphur chemistry. 2020;1-12. Published 2020 Sep 16.<\/p>

[37] Huan C, Xu Y, Zhang W, Guo T,\u00a0 et al. Research Progress on the Antiviral Activity of Glycyrrhizin and its Derivatives in Liquorice. Front Pharmacol. 2021 Jul 6;12:680674.<\/p>

[38] Sun Z, He G, Huang N, et al.\u00a0 Glycyrrhizic Acid: A Natural Plant Ingredient as a Drug Candidate to Treat COVID-19. Frontiers in Pharmacology. 2021 Jul 9;12:707205.<\/p>

[39] Van de Sand L, Bormann M, Alt M, et al. Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease. Viruses. 2021 Apr 2;13(4):609.
[40] Shah MA, Rasul A, Yousaf R, et al. Combination of natural antivirals and potent immune invigorators: A natural remedy to combat COVID-19. Phytotherapy research : PTR. 2021 Aug 15:10.1002\/ptr.7228.
[41] Ng JJ, Choong AMTL. Thromboembolic events in patients with SARS-CoV-2.\u00a0Journal of Vascular Surgery. 2020;72(2):760-761.<\/p>

[42] Potteg\u00e5rd A, Lund LC, Karlstad \u00d8, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.\u00a0BMJ. May 2021;373:n1114.<\/p>

[43] Burn E, Roel E, Pistillo A\u00a0et al. Thromboembolic events and thrombosis with thrombocytopenia after COVID-19 infection and vaccination in Catalonia, Spain. Dostupn\u00e9 na:\u00a0https:\/\/ssrn.com\/abstract=3886421<\/a>.<\/p>

[44] Hubbard GP, Wolffram S, Lovegrove JA, et. Ingestion of quercetin inhibits platelet aggregation and essential components of the collagen-stimulated platelet activation pathway in humans. Journal of thrombosis and haemostasis : JTH. 2004 Dec;2(12):2138-45.<\/p>

[45] Zwicker JI, Schlechter BL, Stopa JD, et al. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. Journal of Clinical Investigation Insight. 2019 Feb 21;4(4):e125851.<\/p>

Spodn\u00e1 \u010das\u0165 formul\u00e1ra<\/p>

[46] Mendes-Silva W, Assafim M, Ruta B, et al.\u00a0 Antithrombotic effect of Glycyrrhizin, a plant-derived thrombin inhibitor. Thromb Res. 2003;112(1-2):93-8.<\/p>

[47] Francischetti IM, Monteiro RQ, Guimar\u00e3es JA. Identification of glycyrrhizin as a thrombin inhibitor. Biochem Biophys Res Commun. 1997 Jun 9;235(1):259-63.<\/p>

[48] Joo HJ, Park JY, Hong SJ, et al.\u00a0 Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment.
The Korean Journal of Internal Medicine.\u00a0 2018 May;33(3):522-531.<\/p>

[49] Kase Y, Okano H. Neurological pathogenesis of SARS-CoV-2 (COVID-19): from virological features to clinical symptoms. Inflammation and Regeneration. 2021 May 7;41(1):15.<\/p>

[50] Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Natural Medicine. 2021 Oct 25. doi: 10.1038\/s41591-021-01556-7.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/i>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

Bernol\u00e1kova 21\/15\n028 01 Trsten\u00e1<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/i>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

lekarenkarmel@gmail.com<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

OTV\u00c1RACIE HODINY<\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
Pondelok – piatok<\/strong><\/div>
6:30 – 17:00<\/strong><\/div>
Sobota<\/strong><\/div>
8:00 – 12:00<\/strong><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Domov \u010cl\u00e1nky Kontakt Je \u010das vr\u00e1ti\u0165 sa k lie\u010divej sile pr\u00edrody. SARS-CoV-2 a in\u00e9 nebezpe\u010dn\u00e9 v\u00edrusov\u00e9 ochorenia; mo\u017enosti prevencie, terapie a rekonvalescencie. \u00a0 Prib\u00fadaj\u00face d\u00f4kazy ukazuj\u00fa, \u017ee vakc\u00edny proti SaRS-CoV-2 neposkytuj\u00fa o\u010dak\u00e1van\u00fa ochranu proti tomuto v\u00edrusu a u pomerne vysok\u00e9ho percenta zao\u010dkovan\u00fdch \u013eud\u00ed doch\u00e1dza k prepuknutiu ochorenia. Napr\u00edklad v \u0161t\u00fadii vykonanej v \u0161t\u00e1te Massachusetts, na …<\/p>\n

\u010cl\u00e1nky<\/span> \u010c\u00edtajte viac »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_canvas","meta":{"_monsterinsights_skip_tracking":false,"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-global-header-display":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":""},"_links":{"self":[{"href":"http:\/\/www.lekarenkarmel.sk\/index.php?rest_route=\/wp\/v2\/pages\/19"}],"collection":[{"href":"http:\/\/www.lekarenkarmel.sk\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.lekarenkarmel.sk\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.lekarenkarmel.sk\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.lekarenkarmel.sk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19"}],"version-history":[{"count":55,"href":"http:\/\/www.lekarenkarmel.sk\/index.php?rest_route=\/wp\/v2\/pages\/19\/revisions"}],"predecessor-version":[{"id":551,"href":"http:\/\/www.lekarenkarmel.sk\/index.php?rest_route=\/wp\/v2\/pages\/19\/revisions\/551"}],"wp:attachment":[{"href":"http:\/\/www.lekarenkarmel.sk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}